Navigation Links
Thoratec Reports First Quarter 2011 Results
Date:5/3/2011

d average number of shares on a fully-diluted basis.  

Non-GAAP shares used to compute diluted net income per share consists of GAAP shares used to compute diluted net income per share adjusted for any inclusions made in conjunction with dilutive impact of Thoratec's convertible debt instruments and any exclusions made in conjunction with the application of the two-class method for calculating net income per share.

Non-GAAP gross profit and gross margin consist of GAAP gross profit and gross margin excluding share-based compensation expense.Non-GAAP operating expenses consist of GAAP operating expenses excluding share-based compensation expense, and amortization of purchased intangibles.

Non-GAAP other income and expense consists of GAAP other income and expenses excluding expenses related to the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt.

Non-GAAP tax expense consists of the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income.

Management believes that it is useful in measuring Thoratec's operations to exclude amortization of intangibles.  These costs are primarily fixed at the time of an acquisition and, unlike other fixed costs that result from ordinary operations, are the result of infrequent and irregular events.

Because of varying valuation methodologies, subjective assumptions and the variety of award types that companies can use, Thoratec management believes that providing non-GAAP financial measures that exclude share-based compensation allows investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods.  The exclusion also enhances investors' ability to review Thoratec's business from the same perspective as Thoratec managemen
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 The Coalition of State Rheumatology ... regional professional rheumatology societies, today released the findings ... perceptions of biosimilars and the potential impact of ... Biosimilars are medicines that are highly similar, but ... different from generic medications in that it is ...
(Date:7/1/2015)... 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief operating ... business and financial update on Wednesday, July 8, 2015 at ... A live audio webcast of the presentation may be accessed ...
(Date:7/1/2015)... 2015 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... taking place in New York, NY ... Hotel. James Sapirstein , Chief ... business during his live presentation and will be available ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... HILLS, Calif., Sept. 15, 2011 HealthTech Capital, a ... emerging HealthTech market, announced today that it has closed ... from HealthTech Capital members in a Series B syndicated ... while Niveus Medical received $600,000 in a Series A ...
... Sept. 15, 2011 CarePoint Partners (CarePoint), a leading ... that it has acquired Mountain State Infusion Services (Mountain ... 14th acquisition in less than four years. CarePoint now ... and is one of the largest independent infusion therapy ...
Cached Medicine Technology:HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market 2HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market 3CarePoint Partners Expands Coverage in the Ohio Valley Region with Acquisition of Mountain State Infusion Services 2
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Sir Fazle ... annual World Food Prize today. Sir Fazle has been recognised for his outstanding contribution ... , Ambassador Ken Quinn, President of the World Food Prize Foundation, announced this ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... retail, long term care, specialty, combo, and compounding pharmacy operations, announces the most ... to the Cardinal Health RBC event at the Venetian Las Vegas, ...
(Date:7/1/2015)... ... 2015 , ... The Collaborative for Children and Families (CCF) announced that it ... allow CCF to improve quality of care and save costs for the child welfare ... many changes in New York’s Medicaid system. Experts agree that children need thorough solutions ...
(Date:7/1/2015)... ... 2015 , ... Did you know that infertility in men is more common ... Advanced Fertility Center of Texas (AFCT) would like to talk about some natural ways ... considered to be a “woman’s issue,” male fertility factors can play a role in ...
(Date:7/1/2015)... Florida (PRWEB) , ... July 01, 2015 , ... ... for society,” said lead author Lisa Stolzenberg, a Professor in FIU’s School of ... juveniles aged 12 to 17 years who participated in the National Survey on ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 2Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 4Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2
... Medivation, Inc.,(Nasdaq: MDVN ) today announced that ... at Cowen and Company,s 28th Annual Health,Care Conference on ... The,Boston Marriott Copley Place in Boston., Dr. Hung ... programs for Dimebon(TM) for Alzheimer,s and Huntington,s,diseases and MDV3100 ...
... Upcoming Federal Mandates, PORTLAND, Ore., March ... generation healthcare connectivity solutions, today announced that,Boston ... as its enterprise ePrescribing solution. This purchase, ... BMC prescribers to securely send,prescriptions from within ...
... of the Company,s, Acquisition Pipeline Gives Management Reason to Remain ... ... SAN JOSE, Calif., March 13 Pet DRx,Corporation ("Pet DRx" or ... and specialized services to companion,animals, today affirmed its 2008 guidance, noting ...
... Execution of Partnership Strategy Provides Nearly $450 Million ... and Committed Cash * 2008 Projected Net Operating Loss Less ... than $450 Million * Conference Call Webcast Thursday, March 13, 08:30 a.m. EDT ... http://www.isispharm.com , CARLSBAD, Calif., March 13 ...
... combination therapy VELCADE, melphalan and prednisone, reported a 32 percent complete ... ... years --, CAMBRIDGE, Mass., March 13 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... Phase I/II clinical trial of the combination therapy,VELCADE, melphalan and prednisone ...
... 13 Echo Therapeutics,(OTC Bulletin Board: ECTE) ... of the Symphony(TM) tCGM System, a novel, ... at the,Tufts Medical Center in Boston, Massachusetts ... to provide patients with diabetes and healthcare,professionals ...
Cached Medicine News:Health News:Boston Medical Center Meets Prescription Challenges With Kryptiq ePrescribing Solution 2Health News:Boston Medical Center Meets Prescription Challenges With Kryptiq ePrescribing Solution 3Health News:Pet DRx Affirms 2008 Guidance 2Health News:Pet DRx Affirms 2008 Guidance 3Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 2Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 3Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 4Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 5Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 6Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 7Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 8Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 9Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 10Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 11Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 12Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 13Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 14Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 15Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 16Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 17Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 18Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 19Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 20Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 21Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 22Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 23Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 24Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 25Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 26Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7
Inquire...
Inquire...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: